Priveterra Acquisition Corp. (NASDAQ:PMGM) announced this afternoon that its special meeting, intended to approve its combination with AEON Biopharma, has been adjourned for the seventh consecutive time.
Given the SPAC’s completion deadline of August 11, it is unlikely that this will be the last adjournment we will see for this completion vote.
Initially scheduled for noon today, the meeting has now been pushed back until June 30 at 4:00 p.m. Priveterra continues to reiterate its commitment to utilizing the extended time during the postponement to further engage with its shareholders.
The deal with AEON Biopharma includes a $40 million minimum cash condition, half of which has already been secured through a $20 million commitment from existing AEON investors at $7 per share. But, Priveterra’s trust, originally totaling $276 million, has been reduced to about $20.3 million after seeing 92.7% of shares redeemed in earlier votes.
Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
At the SPAC of Dawn While the markets digest the impact of the US’ new broad-based tariffs on the rest of the world, SPACs are making their first moves in the new landscape. As SPACInsider previewed in a post yesterday, Hennessy VI (NASDAQ:HCVI) was set to be the first shoe to drop as it had...
The tariffs have landed, and they appear set to define market conditions for the foreseeable future for ongoing SPAC target searches, but even more so for SPACs that have already announced a deal. The trade war comes at an awkward time for SPACs as 60% of pending business combinations – 55 of 91 – are...
At the SPAC of Dawn Trump’s tariffs have finally been unveiled and the markets for the moment are reeling with futures down nearly -3.8% for the Nasdaq and -2.8% for the Dow. International markets have so far seen shallower dips during the day’s trading, which could mean that the waters will calm as the day...
In this SPACInsider Podcast Replay, we go back to 2021, when we spoke with Chris Urmson, CEO and Chairman of autonomous truck technology firm Aurora (NASDAQ:AUR). At the time, Aurora was working to close its $10 billion business combination with Reinvent Technology Y. Chris laid out how the company planned to approach the commercialization of...
As the 2025 market environment settles in, SPACs have an increasingly defined role within the capital markets ecosystem, more often bringing midcap companies public, while traditional IPO deal flow has skewed smaller over time. And, as this new analysis shows, SPACs have been frequently offering investors higher upside when these companies excel. Of course, as...